Applied Genetic Technologies traded at $0.44 this Wednesday August 17th, decreasing $0.04 or 7.81 percent since the previous trading session. Looking back, over the last four weeks, Applied Genetic Technologies lost 21.10 percent. Over the last 12 months, its price fell by 86.74 percent. Looking ahead, we forecast Applied Genetic Technologies to be priced at 0.43 by the end of this quarter and at 0.39 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Applied Genetic Technologies 0.44 -0.04 -7.81% -86.74%
Alimera Sciences 6.69 -0.01 -0.15% 25.52%
Avrobio Inc 1.09 0.02 1.87% -80.61%
Biogen 216.10 -1.48 -0.68% -36.79%
Bluebird Bio 6.78 0.20 3.04% -62.52%
Celldex Therapeutics 36.73 -0.59 -1.58% -17.76%
CTI Biopharma 5.83 0.42 7.76% 120.83%
Gilead Sciences 65.29 -0.73 -1.11% -8.90%
Intercept Pharmaceuticals 18.75 0.02 0.11% 31.86%
Insmed 25.57 -0.20 -0.79% 12.09%
Life Technologies 3.93 -0.04 -1.01% -13.05%
Iveric bio Inc. 12.78 -0.38 -2.89% 40.90%
Ultragenyx Pharmaceutical 47.25 -2.06 -4.18% -42.35%
Regeneron Pharmaceuticals 631.89 -4.45 -0.70% -3.62%
Rigel Pharmaceuticals 1.59 0.03 1.92% -54.57%
Roche Holding 319.10 2.45 0.77% -14.22%
Sanofi 42.18 -2.63 -5.87% -19.87%

Indexes Price Day Year
USND 12917 -21.58 -0.17% -11.18%
US2000 1987 -0.29 -0.01% -6.82%

Applied Genetic Technologies
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.